Shares of thinly traded small-cap biotech Dova Pharmaceuticals Inc (NASDAQ: DOVA) were solidly higher Thursday, adding to the gains they notched early in the week .
Dova announced Tuesday that its Doptelet was granted marketing authorization in Europe for treating severe thrombocytopenia in adult patients with chronic liver disease.
Dova, a pharma company focused on developing therapies for diseases with a high unmet need, said Thursday ahead of the market open that the FDA approved a sNDA for Doptelet. The move expands the use of the drug for treating adults with chronic immune thrombocytopenia who have had an insufficient response to previous treatment.
Thrombocytopenia is a condition in which a patient has a low blood platelet count.
Doptelet, an oral thrombopoietin receptor agonist administered with food, has already been approved for treating thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
Dova said it is evaluating Doptelet for chemotherapy-induced thrombocytopenia and expects top-line results from a Phase 3 study for the indication in the first half of 2020.
Dova shares were up 16.15% at $12.30 at the time of publication Thursday.
The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO
BridgeBio Pharma IPO: What You Need To Know
Photo by Prof. Erhabor Osaro/Wikimedia.
See more from Benzinga
- The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.